Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-194 manufacturers

Filters

Filters

Filters , active

Country of origin : Israel
1 products found

pp-194

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
Israel
GMP approvals
Israel
Comments
Indication: Pancreatic ductal adenocarcinoma (PDAC) — Phase 2b planned in combination with chemotherapy Clinical stage: Phase 2b — planned H2 2025 (following positive Phase 2a signal) Modality: Biological (first-in-class anti-CEACAM1 monoclonal antibody) Mechanism / Target: First-in-class antibody targeting CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1); dual mechanism: (1) blocks CEACAM1-mediated T-cell immune checkpoint restoring cytotoxic T-cell activity; (2) disrupts CEACAM1–EGF receptor oncogenic interaction promoting tumour survival Route / form: IV infusion Differentiation: First-in-class anti-CEACAM1 immunotherapy; dual immune checkpoint and tumour survival blocking mechanism; addresses PDAC — a tumour type resistant to current immunotherapy; Phase 2b planned in pancreatic cancer where no approved immunotherapy exists;
Manufacturer #39334

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.